Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure
Tài liệu tham khảo
Steg, 2004, Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE), Circulation, 109, 494, 10.1161/01.CIR.0000109691.16944.DA
Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001
Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207
Pitt, 2005, Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure, J Am Coll Cardiol, 46, 425, 10.1016/j.jacc.2005.04.038
Borghi, 1999, Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of myocardial infarction long-term evaluation, Am J Hypertens, 12, 665, 10.1016/S0895-7061(99)00042-4
Solomon, 2005, Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both, N Engl J Med, 352, 2581, 10.1056/NEJMoa043938
Cannon, 2001, Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban, N Engl J Med, 344, 1879, 10.1056/NEJM200106213442501
Wallentin, 2000, Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Fast revascularisation during instability in coronary artery disease, Lancet, 356, 9, 10.1016/S0140-6736(00)02427-2